Anti-Mullerian hormone levels during hormonal contraception in women with polycystic ovary syndrome

Basit Öğe Kaydı
dc.contributor.authorSomunkıran, Aslı
dc.contributor.authorYavuz, Tevfik
dc.contributor.authorYücel, Oğuz
dc.contributor.authorÖzdemir, İsmail
dc.date.accessioned2020-04-30T22:39:29Z
dc.date.available2020-04-30T22:39:29Z
dc.date.issued2007
dc.departmentDÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.descriptionWOS: 000250695700012en_US
dc.descriptionPubMed: 17335955en_US
dc.description.abstractObjective: The use of oral contraceptive (OC) pills alters the characteristic features of polycystic ovary syndrome (PCOS) complicating the diagnosis of this disease. Anti-Mullerian hormone (AMH) levels are high in PCOS patients and are stable throughout the menstrual cycle in healthy subjects. This study examined the influence of hormonal suppression with OC therapy on the serum AMH levels in women with PCOS and with normal menstrual cycles. Study design: Thirty women with PCOS and 15 women with normal menstrual cycles were enrolled in this prospective study. Serum was collected from the subjects during the early follicular phase of the menstrual cycle and after the sixth cycle of oral contraceptive therapy, and stored frozen until assayed. The effect of OC therapy on the serum AMH, estradiol (EA luteinizing hormone (LH), follicle-stimulating hormone (FSH), free testosterone, total testosterone, and dehydroepiandrosterone sulfate (DHEA-S) levels was studied. In addition, ovarian volume and follicle count were assessed. Results: The serum AMH levels in PCOS patients were significantly higher than in healthy women at baseline (+/- S.D.; 5.49 +/- 2.26 and 1.93 +/- 0.51 ng/ml, respectively; p = 0.001). After six cycles of OC therapy, no significant changes in the AMH levels were observed in either the PCOS patients or normally cycling women. Ultrasound showed significant reductions in ovarian volume and follicle number and size at 6 months in both groups. Conclusion: Although significant reductions were observed in ovarian volume and follicle number, 6 months of contraceptive therapy did not change the serum AMH concentration in either group. AMH may be considered a new marker in PCOS patients who are already on contraceptive treatment. (C) 2007 Elsevier Ireland Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/j.ejogrb.2007.01.012en_US
dc.identifier.endpage201en_US
dc.identifier.issn0301-2115
dc.identifier.issue2en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage196en_US
dc.identifier.urihttps://doi.org/10.1016/j.ejogrb.2007.01.012
dc.identifier.urihttps://hdl.handle.net/20.500.12684/2739
dc.identifier.volume134en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherElsevier Ireland Ltden_US
dc.relation.ispartofEuropean Journal Of Obstetrics Gynecology And Reproductive Biologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectanti-mullerian hormoneen_US
dc.subjectmullerian-inhibiting substanceen_US
dc.subjectPolycystic ovary syndromeen_US
dc.subjectoral contraceptive pillsen_US
dc.titleAnti-Mullerian hormone levels during hormonal contraception in women with polycystic ovary syndromeen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
2739.pdf
Boyut:
320.99 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu